Fig. 2From: Required concentration index quantifies effective drug combinations against hepatitis C virus infectionRanking anti-HCV mono drug treatments against genotypes 1b and 2a: The critical dose of antiviral drug (i.e., fold increase of IC50) required to inhibit viral replication by 95%, i.e., RCI95, was calculated for HCV (a) genotype 1b and (b) genotype 2aBack to article page